ImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics Innovation
ImmunoPrecise Antibodies (NASDAQ: IPA) announces its upcoming TECHDAY event on November 15, 2024, in Cambridge, Massachusetts. The event will showcase the company's latest advancements in AI-driven drug discovery and biologics innovation. Key presentations include Dr. Van Hyfte's demonstration of the LENSai platform, featuring HYFT® Universal Fingerprints for multi-omics integration, and Dr. Sato's presentation on IPA's B Cell Discovery Platform with AI and NGS workflows. The event includes a fireside chat on drug discovery through data integration and AI-powered insights, featuring collaboration with InterSystems IRIS data platform.
ImmunoPrecise Antibodies (NASDAQ: IPA) annuncia il suo prossimo evento TECHDAY, che si terrà il 15 novembre 2024 a Cambridge, Massachusetts. L'evento metterà in mostra i più recenti progressi dell'azienda nella scoperta di farmaci guidata dall'IA e nell'innovazione dei biologici. Le presentazioni principali includono la dimostrazione del piattaforma LENSai da parte del Dr. Van Hyfte, che presenta gli HYFT® Universal Fingerprints per l'integrazione multi-omica, e la presentazione del Dr. Sato sulla Piattaforma di Scoperta delle cellule B di IPA con flussi di lavoro di IA e NGS. L'evento includerà una chiacchierata informale sulla scoperta di farmaci attraverso l'integrazione dei dati e le intuizioni potenziate dall'IA, con la collaborazione della piattaforma dati InterSystems IRIS.
ImmunoPrecise Antibodies (NASDAQ: IPA) anuncia su próximo evento TECHDAY el 15 de noviembre de 2024 en Cambridge, Massachusetts. El evento mostrará los últimos avances de la compañía en descubrimiento de fármacos impulsado por IA e innovación en biológicos. Las presentaciones clave incluyen la demostración de la plataforma LENSai por parte del Dr. Van Hyfte, que presenta los HUFT® Universal Fingerprints para la integración multi-ómica, y la presentación del Dr. Sato sobre la Plataforma de Descubrimiento de Células B de IPA con flujos de trabajo de IA y NGS. El evento incluirá una charla informal sobre el descubrimiento de fármacos a través de la integración de datos y las percepciones impulsadas por IA, con colaboración de la plataforma de datos InterSystems IRIS.
ImmunoPrecise Antibodies (NASDAQ: IPA)는 2024년 11월 15일 매사추세츠주 케임브리지에서 열릴 예정인 TECHDAY 이벤트를 발표했습니다. 이 행사는 AI 기반 약물 발견 및 생물학 혁신에 대한 회사의 최신 발전을 선보일 예정입니다. 주요 발표로는 Van Hyfte 박사가 다중 오믹스 통합을 위한 HYFT® 유니버설 핑거프린트를 특징으로 하는 LENSai 플랫폼을 시연하고, Sato 박사가 IA와 NGS 작업 흐름을 통한 IPA의 B 세포 발견 플랫폼에 대해 발표합니다. 이 행사에서는 데이터 통합과 AI 기반 통찰력을 통한 약물 발견에 관한 화기애애한 대화가 진행되며, InterSystems IRIS 데이터 플랫폼과의 협업이 포함됩니다.
ImmunoPrecise Antibodies (NASDAQ: IPA) annonce son prochain événement TECHDAY le 15 novembre 2024 à Cambridge, Massachusetts. Cet événement mettra en avant les dernières avancées de l'entreprise en matière de découverte de médicaments guidée par l'IA et d'innovation biologique. Parmi les présentations clés, le Dr Van Hyfte démontrera la plateforme LENSai, présentant les empreintes digitales universelles HYFT® pour l'intégration multi-omique, et le Dr Sato présentera la plateforme de découverte des cellules B d'IPA avec des flux de travail IA et NGS. L'événement comprendra une discussion informelle sur la découverte de médicaments à travers l'intégration des données et les insights propulsés par l'IA, en collaboration avec la plateforme de données InterSystems IRIS.
ImmunoPrecise Antibodies (NASDAQ: IPA) kündigt sein bevorstehendes TECHDAY-Event am 15. November 2024 in Cambridge, Massachusetts, an. Die Veranstaltung wird die neuesten Fortschritte des Unternehmens im Bereich KI-gesteuerte Arzneimittelentdeckung und Innovationen in der Biologics zeigen. Zu den Hauptpräsentationen gehört die Demonstration der LENSai-Plattform durch Dr. Van Hyfte, die HYFT® Universal Fingerprints für die Multi-Omics-Integration vorstellt, sowie die Präsentation von Dr. Sato zur B-Zell-Entdeckungsplattform von IPA mit KI- und NGS-Workflows. Die Veranstaltung umfasst ein informelles Gespräch über Arzneimittelentdeckung durch Datenintegration und KI-gestützte Einblicke, in Zusammenarbeit mit der InterSystems IRIS-Datenplattform.
- Development of LENSai platform integrating biotechnology and AI for drug discovery
- Strategic partnership with InterSystems for data integration solutions
- Advanced B Cell Discovery Platform with AI and NGS workflow integration
- None.
Highlights of TECHDAY:
- Presentation by Dr. Dirk Van Hyfte: Dr. Van Hyfte will present “Accelerating Drug Discovery with LENSai: A Comprehensive Solution.” He will showcase LENSai, BioStrand’s revolutionary platform, and discuss how it transforms drug discovery by integrating biotechnology, biotherapeutics, and artificial intelligence. Key topics include using HYFT® Universal Fingerprints to revolutionize multi-omics and data integration while accelerating drug discovery, development and optimization with AI-driven insights.
- LENSai Demo: A live demonstration of the LENSai platform, showcasing its capabilities in accelerating and enhancing the discovery and design of therapeutic antibodies through AI-driven insights.
-
Presentation by Dr. Shuji Sato: Dr. Sato will present IPA’s B Cell Discovery Platform and discuss its integration with the company’s advanced AI and NGS workflows for highly efficient hit expansion. This process includes:
- Fast analysis of complete NGS repertoires
- Multimodal feature extraction that combines sequence, structure, and large language model (LLM) embeddings to deliver enhanced insights into sample diversity.
- Add-ons that complement outputs from phage display, B-cell, and hybridoma technologies, enabling the retrieval of antibody sequences with characteristics similar to known binders.
-
Fireside Chat: Disruptive Dialogue: Empowering Drug Discovery Through Seamless Data Integration and AI-Powered Insights
Participants:- Dr. Dirk Van Hyfte, Head of Innovation and Co-founder, BioStrand (IPA)
- Jeff Fried, Director of Platform Strategy and Innovation, InterSystems
This discussion will explore how vector search intelligence is at the core of the LENSai platform, seamlessly integrated with the InterSystems IRIS data platform to deliver precise, scalable solutions that accelerate antibody discovery, enhance accuracy, and increase candidate diversity.
AI-Driven Drug Discovery Summit
Additionally, earlier that same week at the AI-Driven Drug Discovery Summit
Participants at the AI-Driven Drug Discovery Summit
- Adam Root, Vice President and Head of Protein Sciences, Generate Biomedicines
- Dr. Dirk Van Hyfte, Head of Innovation and Co-founder, BioStrand (IPA)
The chat will focus on the integration of artificial intelligence and machine learning with wet lab infrastructure to accelerate biologics development.
A recorded webcast of the TECHDAY presentations will be available in the Investors section of the IPA website under "Events and Presentations" at ir.ipatherapeutics.com.
Interested in joining us for this exclusive TECHDAY experience? Space is limited - secure your spot by contacting Jennifer K. Zimmons, PhD, MBA, at Quantum Media: jen@quantum-corp.com
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable
Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the Company’s Annual Report on Form 20-F for the year ended April 30, 2024 (which may be viewed on the Company’s SEDAR+ profile at www.sedarplus.ca and EDGAR profile at www.sec.gov/edgar). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. Accordingly, readers should not place undue reliance on forward-looking statements contained in this news release. The forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. The Company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241104713145/en/
Investor Relations Contact
Kirsten Beduya
Quantum Media Group, LLC
kirsten@quantum-corp.com
Source: ImmunoPrecise Antibodies Ltd.
FAQ
When is ImmunoPrecise Antibodies (IPA) hosting its TECHDAY event in 2024?
What will be showcased at IPA's TECHDAY 2024?